血清MMP1和P53自身抗体联合检测对食管鳞状细胞癌的诊断价值

doi:10.3969/j.issn.1004-616x.2024.04.010

Abstract

Abstract: OBJECTIVE：To evaluate diagnostic values from the combined detection of serum MMP1 and P53 autoantibody in patients with esophageal squamous cell carcinoma (ESCC). METHODS：The study included 93 ESCC patients hospitalized in the Cancer hospital of Shantou University Medical College and 90 physical examination subjects as normal controls. Serum levels of MMP1 and P53 autoantibodies were measured by enzyme-linked immunosorbent assay (ELISA). The diagnostic value was evaluated using the receiver operating characteristic (ROC) curve. RESULTS：The serum levels of MMP1 and P53 autoantibodies of ESCC patients were higher than those in normal controls (P<0.01). ROC curves showed that the area under curve (AUC) of MMP1 in ESCC diagnosis was 0.700 (95%CI：0.624-0.776). When the optimum diagnostic cutoff was 7.248 ng/mL， the sensitivity was 52.7%，and the specificity was 83.3%. Measurement of P53 autoantibodies demonstrated an AUC of 0.713 (95%CI：0.638-0.788)，with the diagnostic cutoff of 0.080 and a sensitivity/specificity of 49.5%/83.3%. The combination of MMP1 and P53 autoantibodies yielded an AUC of 0.787 (95%CI：0.720-0.854)，a sensitivity of 66.7% and a specificity of 83.3%. In early-stage ESCC，combined detection of MMP1 and P53 autoantibodies provided good diagnostic power (AUC=0.760；95%CI：0.663-0.857)，with 66.7% sensitivity and 83.3% specificity. CONCLUSION：Serum MMP1 and P53 autoantibody were both over-expressed in ESCC patients. The use of both biomarkers was helpful in making early diagnosis of ESCC.

Key words: matrix metalloproteinase 1, P53 autoantibody, esophageal squamous cell carcinoma, early diagnosis

CLC Number:

R735.1

HUANG Xiaoyan, WU Fangcai, LIU Cantong, HUANG Jiatao, XU Yiwei. Detection of both serum MMP1 and P53 autoantibody for the diagnosis of esophageal squamous cell carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 305-308,324.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020; GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3); 209-249.
[2] QU H T, LI Q, HAO L, et al. Esophageal cancer screening, early detection and treatment; current insights and future directions[J]. World J Gastrointest Oncol, 2024, 16(4); 1180- 1191.
[3] LIU M, HU Y, ZHANG M F, et al. MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma [J]. Cancer Lett, 2016, 377(1); 97-104.
[4] 田丽贞, 韩润焜, 田丽如. 食管癌血清标志物的生物信息学筛选及其临床诊断价值验证[J]. 转化医学杂志, 2020, 9(6); 351-355.
[5] CHEN Y K, TUNG C W, LEE J Y, et al. Plasma matrix metalloproteinase 1 improves the detection and survival prediction of esophageal squamous cell carcinoma[J]. Sci Rep, 2016, 6; 30057.
[6] YANG R Z, HAN Y, YI W J, et al. Autoantibodies as biomarkers for breast cancer diagnosis and prognosis[J]. Front Immunol, 2022, 13; 1035402.
[7] LIU S X, TAN Q Y, SONG Y Y, et al. Anti-p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer; a meta-analysis[J]. Scand J Immunol, 2020, 91(2); e12829.
[8] KATHRIKOLLY T, NAIR S N, MATHEW A, et al. Can serum autoantibodies be a potential early detection biomarker for breast cancer in women? A diagnostic test accuracy review and meta-analysis[J]. Syst Rev, 2022, 11(1); 215.
[9] XU Y W, PENG Y H, CHEN B, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma[J]. Am J Gastroenterol, 2014, 109(1); 36-45.
[10] RICE T W, ISHWARAN H, FERGUSON M K, et al. Cancer of the esophagus and esophagogastric junction; an eighth edition staging primer[J]. J Thorac Oncol, 2017, 12(1); 36-42.
[11] LARONHA H, CALDEIRA J. Structure and function of human matrix metalloproteinases[J]. Cells, 2020, 9(5); 1076.
[12] BASSIOUNI W, ALI M A M, SCHULZ R. Multifunctional intracellular matrix metalloproteinases; implications in disease [J]. FEBS J, 2021, 288(24); 7162-7182.
[13] NG L, WONG S K, HUANG Z, et al. CD26 induces colorectal cancer angiogenesis and metastasis through CAV1/MMP1 signaling[J]. Int J Mol Sci, 2022, 23(3); 1181.
[14] CHEN Y T, PENG S Q, CEN H, et al. MicroRNA hsa-miR- 623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer[J]. Int J Oncol, 2019, 55(1); 142-156.
[15] ATTALLAH A M, ALBANNAN M S, EL-DEEN M S, et al. Diagnostic role of collagen-III and matrix metalloproteinase-1 for early detection of hepatocellular carcinoma[J]. Br J Biomed Sci, 2020, 77(2); 58-63.
[16] ANDO W, KIKUCHI K, UEMATSU T, et al. Novel breast cancer screening; combined expression of miR-21 and MMP-1 in urinary exosomes detects 95% of breast cancer without metastasis[J]. Sci Rep, 2019, 9(1); 13595.
[17] SHEN Q J, POLOM K, WILLIAMS C, et al. A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer[J]. EBioMedicine, 2019, 44; 322-333.
[18] KIKUCHI Y, SHIMADA H, YAMASAKI F, et al. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2[J]. Int J Clin Oncol, 2024, 29(5); 512-534.

Detection of both serum MMP1 and P53 autoantibody for the diagnosis of esophageal squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LIU Ruixue, LI Desheng, ZHANG Liwei. Characteristics of serum lipidomics among Kazakhs with esophageal squamous cell carcinomas based on the UPLC-MS/MS method [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 21-28,34.
[2]	HUANG Conggai, LIU Qing, ZHENG Shutao, LIU Tao, TAN Yiyi, PENG Tianyuan, CHEN Jiao, LU Xiaomei. Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 53-57,65.
[3]	ZHENG Yaqi, ZHAO Ziting, PAN Deyuan, LIU Luxin, XU Xiue, LIAO Liandi, WANG Shaohong, LI Enmin, XU Liyan. The expression of tonsoku-like DNA repair protein in esophageal carcinoma and its effect on the proliferation of esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 412-419.
[4]	WANG Yinong, LIU Guozheng, XIE Guanchao, FENG Dan, LI Sai, CAI Yan, ZHANG Yu, WANG Mingrong, HAO Jiajie. Inhibitory effects of ANXA2 knockdown on malignant phenotype of esophageal squamous carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 445-451.
[5]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[6]	SHI Jianhong, CHEN Dingxiong, LU Xiaotong, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Inhibitory effect of ICG-001 on proliferation of esophageal squamous carcinoma cells and its molecular mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 187-191,196.
[7]	FENG Dan, FAN Zhilu, WANG Yinong, LI Sai, GUO Jing, CAI Yan, ZHANG Yu, WEI Wenqiang, WANG Mingrong, HAO Jiajie. P4HA2 promotes proliferation of esophageal squamous carcinoma cells via activating the EGFR/AKT/S6 signaling pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 87-94,101.
[8]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.
[9]	CUI Wenxuan, JIAO Wenjing, ZHAO Wei, DU Yanyan, TIAN Guo, ZHANG Jinyan, MA Ming. Clinical values of combined FIB, FAR and serum tumor markers in diagnosis and progression of ESCC patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 289-294,326.
[10]	YANG Xingxiao, ZHANG Xueyuan, ZOU Naiyi, SHAN Bao'en, MA Ming, ZHU Shuchai. Effects of HMGB1 silencing on migration, invasion and radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 327-333.
[11]	YANG Liyan, LIU Zou, HAO Jiajie, ZHANG Yu, WANG Mingrong. Study on the mechanism of nucleo-plasma translocation of p62 protein in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 338-344.
[12]	CHANG Chen, YANG Liyan, CAI Hongqing, YUAN Qing, HAO Jiajie, WANG Mingrong. Expressions and clinical implications of SERPINE1 mRNA in esophageal squamous carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 245-249.
[13]	ZHENG Junwen, CHANG Chen, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Investigation on expression and function of NEDD4 in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 203-207,224.
[14]	JIAO Wenjing, GUO Xiujuan, SHAO Junguo, JIAO Wenpeng, ZHANG Jinyan. Relationships among blood cell ratios, clinicopathological characteristics and prognosis in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 213-217.
[15]	ZHANG Die, LIU Xianghe, HUO Miaomiao, LIU Mei, XU Ningzhi, ZHU Hongxia. Effects of miR-195-5p on radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 81-88,94.